EOLS Evolus, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1570562 · Fiscal year ends 12/31
Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.1%
TTM net income YoY-16.5%
TTM EPS YoY-7.8%
Revenue 3-yr CAGR28.0%
Net income 3-yr CAGR—
Margins
Gross margin67.2%
Operating margin-15.5%
Net margin-22.3%
FCF margin-15.5%
EBITDA margin-14.0%
Returns
ROE-18,729.6%
ROA-26.8%
ROIC (approx.)-61.1%
Asset turnover1.20x
Leverage & solvency
Liabilities / assets108.2%
Debt / equity—
Current ratio2.27x
Interest coverage-2.06x
Cash quality & payout
Operating cash flow / net income0.67x
Accruals ratio-8.9%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $297.18M | $266.27M | $202.09M | $148.62M | $99.67M |
| Cost of revenue | $100.07M | $83.97M | $64.51M | $58.84M | $43.53M |
| Gross profit | $197.11M | $182.30M | $137.57M | $89.77M | $56.14M |
| R&D expense | $9.58M | $9.17M | $6.56M | $4.74M | $2.06M |
| SG&A expense | $220.79M | $198.03M | $164.94M | $141.84M | $112.07M |
| Operating income | -$32.66M | -$34.41M | -$49.23M | -$65.33M | -$44.41M |
| Interest expense | $19.69M | $18.73M | $13.83M | $9.10M | $1.40M |
| Pretax income | -$50.96M | -$49.76M | -$61.51M | -$74.32M | -$46.77M |
| Income tax | $677,000 | $664,000 | $176,000 | $95,000 | $42,000 |
| Net income | -$51.64M | -$50.42M | -$61.69M | -$74.41M | -$46.81M |
| EBITDA | -$25.16M | -$29.11M | -$44.10M | -$61.61M | -$38.78M |
| EPS (basic) | -0.80 | -0.81 | -1.08 | -1.33 | -0.94 |
| EPS (diluted) | -0.80 | -0.81 | -1.08 | -1.33 | -0.94 |
| Weighted avg. shares (diluted) | 64.47M | 62.02M | 56.92M | 56.07M | 49.77M |
| Balance sheet | |||||
| Cash & equivalents | $53.83M | $86.95M | $62.84M | $53.92M | $146.26M |
| Short-term investments | — | — | — | — | $0 |
| Receivables | $54.70M | $47.68M | $30.53M | $22.45M | $14.66M |
| Inventory | $26.96M | $12.16M | $11.00M | $18.85M | $1.76M |
| Current assets | $142.92M | $151.34M | $112.42M | $100.80M | $178.80M |
| PP&E, net | $5.37M | $3.22M | $2.09M | $2.62M | $1.37M |
| Goodwill | $21.21M | $21.21M | $21.21M | $21.21M | $21.21M |
| Intangibles | $48.04M | $48.75M | $47.11M | $48.60M | $50.62M |
| Total assets | $225.87M | $232.57M | $189.00M | $177.98M | $257.48M |
| Current liabilities | $75.31M | $62.96M | $48.29M | $46.51M | $57.66M |
| Long-term debt | $146.10M | $121.51M | $120.36M | $71.88M | $71.22M |
| Total debt | $146.10M | $121.51M | $120.36M | $71.88M | $71.22M |
| Total liabilities | $248.97M | $227.05M | $209.69M | $159.48M | $175.61M |
| Shareholders' equity | -$23.11M | $5.52M | -$20.69M | $18.50M | $81.88M |
| Net debt | $92.27M | $34.55M | $57.52M | $17.96M | -$75.03M |
| Shares outstanding | 65.01M | 63.50M | 57.82M | 56.26M | 55.58M |
| Cash flow statement | |||||
| Operating cash flow | -$42.27M | -$18.00M | -$34.01M | -$84.91M | -$33.39M |
| Capital expenditure | $3.44M | $1.47M | $473,000 | $1.62M | $393,000 |
| Free cash flow | -$45.71M | -$19.47M | -$34.48M | -$86.53M | -$33.78M |
| Investing cash flow | -$8.45M | -$4.82M | -$1.63M | -$2.94M | $4.03M |
| Financing cash flow | $17.34M | $47.41M | $44.64M | -$4.15M | $73.05M |
| Depreciation & amortization | $7.51M | $5.30M | $5.13M | $3.72M | $5.62M |
| Stock-based compensation | $20.70M | $22.25M | $16.46M | $10.83M | $9.58M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.